Artemis Medicare

Why is Artemis Medicare Services Ltd falling/rising?

As of 23-Jun, the stock price of Artemis Medicare Services Ltd is 266.20, down 0.89% due to underperformance in its sector. Despite recent mixed performance and strong long-term growth, the decline is influenced by a high percentage of pledged shares among promoters.

As of 23-Jun, the stock price of Artemis Medicare Services Ltd is currently at 266.20, reflecting a decrease of 2.4 points or 0.89%. This decline can be attributed to its performance today, where it underperformed its sector by 1.25%. Despite touching an intraday high of Rs 276 earlier in the day, the overall trend indicates a downward movement.<BR><BR>In the context of recent performance, the stock has shown a mixed picture. Over the past week, it has increased by 1.88%, while it has decreased by 2.74% over the past month. Year-to-date, the stock has a slight decline of 1.77%, contrasting with a more favorable annual return of 6.06%. However, the stock's performance over the last three years has been strong, with a remarkable increase of 143.17%, significantly outperforming the benchmark Sensex.<BR><BR>Investor participation has risen, as indicated by a delivery volume increase of 124.35% against the 5-day average, suggesting that there is interest in the stock despite its current price drop. Additionally, the company has demonstrated a strong ability to service its debt and has reported positive results for the last nine consecutive quarters, which supports its long-term growth potential.<BR><BR>However, a significant risk factor contributing to the stock's decline is that 44.53% of promoter shares are pledged. In a falling market, this high level of pledged shares can exert additional downward pressure on stock prices. Therefore, while there are positive indicators for Artemis Medicare Services Ltd, the current price decline is influenced by its underperformance today and the risks associated with pledged shares.

Which are the latest news on Artemis Medicare?

What does Artemis Medicare do?

Artemis Medicare Services Ltd manages multi-specialty hospitals, with its flagship Artemis Hospital established in 2007. As of March 2026, it reported net sales of ₹279 Cr and a net profit of ₹30 Cr, with a market cap of ₹4,118 Cr.

Overview: <BR>Artemis Medicare Services Ltd is engaged in managing and operating multi-specialty hospitals within the small-cap hospital industry.<BR><BR>History: <BR>The company was incorporated on May 18, 2004, and commenced commercial operations by establishing Artemis Hospital (formerly Artemis Health Institute) in Gurugram on July 16, 2007. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 279 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 30 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 4,118 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.15% <BR>Debt-Equity: 0.06 <BR>Return on Equity: 11.33% <BR>Price-to-Book: 4.39 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Artemis Medicare?

As of 10th June, Artemis Medicare Services Ltd has a market capitalization of 4,118.00 Cr, with recent net sales of 1,081.24 Cr and a net profit of 103.62 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Artemis Medicare Services Ltd has a market capitalization of 4,118.00 Cr, which classifies it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,081.24 Cr, while the sum of Net Profit for the same period is 103.62 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 837.68 Cr, and Total Assets amount to 1,357.41 Cr.

Who are in the management team of Artemis Medicare?

The management team of Artemis Medicare includes Managing Director Devlina Chakravarty, Chairman Onkar S Kanwar, and several directors such as Nirmal Kumar Ganguly, Neeraj Kanwar, and Shalini Kanwar Chand, along with Company Secretary Poonam Makkar and independent directors like Deepa Gopalan Wadhwa and Sunil Tandon. This diverse team brings a wealth of expertise to the company.

The management team of Artemis Medicare includes the following key members:<BR><BR>1. **Devlina Chakravarty** - Managing Director<BR>2. **Onkar S Kanwar** - Chairman & Director<BR>3. **Nirmal Kumar Ganguly** - Director<BR>4. **Neeraj Kanwar** - Director<BR>5. **Shalini Kanwar Chand** - Director<BR>6. **Poonam Makkar** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several independent directors on the board, including:<BR><BR>- **Deepa Gopalan Wadhwa**<BR>- **Sunil Tandon**<BR>- **S Narayan**<BR>- **Sanjaya Baru**<BR>- **Sanjib Sen**<BR><BR>This diverse management team brings a range of expertise to the company.

Who are the peers of the Artemis Medicare?

Peers of Artemis Medicare include Health.Global, Jupiter Life Lin, Yatharth Hospital, Jeena Sikho, Kovai Medical, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and Shalby. In terms of performance, Yatharth Hospital leads with a 57.94% return, while Artemis Medicare has a -2.45% return.

Peers: The peers of Artemis Medicare are Health.Global, Jupiter Life Lin, Yatharth Hospit., Jeena Sikho, Kovai Medical, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and Shalby.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin and Kovai Medical, while Average management risk is found at Health.Global, Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and Shalby. Below Average management risk is noted at Yatharth Hospit. In terms of growth, Excellent growth is seen at Yatharth Hospit., Artemis Medicare, Jeena Sikho, and Dr Agarwal's Eye, while Good growth is reported at Jupiter Life Lin, Kovai Medical, Indrapr.Medical, and KMC Speciality. Average growth is present at Health.Global and Shalby, and Below Average growth is noted at Jupiter Life Lin. For capital structure, Excellent capital structure is found at Jupiter Life Lin, Yatharth Hospit., Indrapr.Medical, and KMC Speciality, while Good capital structure is observed at Kovai Medical and Artemis Medicare, and Below Average capital structure is noted at Health.Global and Dr Agarwal's Eye.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Yatharth Hospit. at 57.94%, while the peer with the lowest is Jupiter Life Lin at -13.75%. Artemis Medicare's 1-year return is -2.45%, which is higher than Jupiter Life Lin's but lower than Yatharth Hospit.'s. Additionally, the peers with negative six-month returns include Health.Global, Indrapr.Medical, Dr Agarwal's Eye, and Shalby.

Should I buy, sell or hold Artemis Medicare Services Ltd?

Are Artemis Medicare Services Ltd latest results good or bad?

Artemis Medicare Services Ltd's latest results are generally positive, with a 34.42% increase in net profit and improved operating margins at 18.48%. However, persistent margin volatility throughout the year raises concerns about the sustainability of these profitability gains.

Artemis Medicare Services Ltd's latest results show a mixed picture, but overall, they can be considered positive. In Q4 FY26, the company reported a net profit of ₹30.03 crores, which is a significant increase of 34.42% compared to the previous quarter and up 30.40% year-on-year. Revenue also grew, reaching ₹279.23 crores, reflecting a 2.53% increase quarter-on-quarter and a 16.39% increase year-on-year.<BR><BR>One of the highlights of the results is the operating margin, which improved to 18.48%, marking the highest level in seven quarters and a notable increase from the previous year. This improvement in margins was attributed to better cost management and operational efficiency.<BR><BR>However, it's important to note that there has been persistent margin volatility throughout the fiscal year, with operating margins fluctuating significantly across quarters. This raises questions about the sustainability of the profitability improvements. <BR><BR>Overall, while the financial performance in Q4 is strong, the volatility in margins suggests that investors should monitor future results closely to determine if these improvements can be maintained.

When is the next results date for Artemis Medicare Services Ltd?

The next results date for Artemis Medicare Services Ltd is February 2, 2026.

The next results date for Artemis Medicare Services Ltd is scheduled for February 2, 2026.

Is Artemis Medicare technically bullish or bearish?

As of December 2, 2025, the trend has shifted to bullish with moderate strength, supported by positive indicators like the MACD, RSI, and moving averages, although caution is advised due to some bearish signals on the monthly timeframe.

As of 2 December 2025, the technical trend has changed from mildly bearish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include a bullish MACD on the weekly chart, a bullish RSI on the monthly chart, and bullish signals from moving averages on the daily timeframe. The KST and OBV are also bullish on the weekly timeframe, while the Bollinger Bands show a mildly bullish trend. However, the monthly MACD and KST remain mildly bearish, indicating some caution. Overall, the bullish trend is supported by recent price action, despite a recent decline from the previous close.

How has been the historical performance of Artemis Medicare?

Artemis Medicare has shown consistent growth, with net sales increasing from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, and profit after tax rising from INR 31.40 crore to INR 82.18 crore during the same period. The company has improved its operating profit margin and cash flow, indicating strong operational efficiency.

Answer:<BR>The historical performance of Artemis Medicare shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Artemis Medicare's net sales have increased significantly from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025. Operating profit (PBDIT) also saw substantial growth, climbing from INR 71.35 crore in March 2022 to INR 184.78 crore in March 2025, with an operating profit margin that improved from 12.16% to 16.2% over the same period. Profit before tax increased from INR 37.18 crore in March 2022 to INR 107.67 crore in March 2025, and profit after tax rose from INR 31.40 crore to INR 82.18 crore. The company's total assets grew from INR 709.66 crore in March 2022 to INR 1,357.41 crore in March 2025, while total liabilities increased from INR 709.66 crore to INR 1,357.41 crore as well. Cash flow from operating activities improved from INR 59 crore in March 2022 to INR 145 crore in March 2025, indicating enhanced operational efficiency. Overall, Artemis Medicare has demonstrated robust growth in sales, profits, and asset base, positioning itself favorably in the market.

Is Artemis Medicare overvalued or undervalued?

As of October 16, 2025, Artemis Medicare is considered fairly valued with a PE ratio of 38.36 and a favorable comparison to peers like Apollo Hospitals and Max Healthcare, despite a recent underperformance against the Sensex, but it shows strong long-term growth potential.

As of 16 October 2025, Artemis Medicare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 38.36, an EV to EBITDA of 20.65, and a PEG ratio of 0.72, which suggests a reasonable growth expectation relative to its price.<BR><BR>In comparison to its peers, Artemis Medicare's valuation appears more favorable. For instance, Apollo Hospitals, which is also rated attractive, has a significantly higher PE ratio of 71.71, while Max Healthcare is categorized as very expensive with a PE of 94.88. Despite recent underperformance compared to the Sensex, with a year-to-date return of -23.26% versus the Sensex's 6.82%, Artemis Medicare's strong growth in the long term, as evidenced by a 273.78% return over three years, reinforces its attractiveness in the market.

Who are the top shareholders of the Artemis Medicare?

The top shareholder of Artemis Medicare is Constructive Finance Private Limited, holding 67.17%. Other significant shareholders include the Governor of Kerala at 4.91%, mutual funds at 1.96%, foreign institutional investors at 0.31%, and individual investors with a collective stake of 12.86%.

The top shareholders of Artemis Medicare primarily include the promoters, with Constructive Finance Private Limited holding the highest stake at 67.17%. The promoters collectively have a significant portion of the shares, with 44.53% of their holdings pledged. In terms of public shareholders, the Governor of Kerala is the largest, holding 4.91%. Additionally, mutual funds hold 1.96% across four schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.31% through 24 different entities. Individual investors collectively own 12.86% of the company.

Has Artemis Medicare declared dividend?

Artemis Medicare Services Ltd has declared a 45% dividend, amounting to 0.45 per share, with an ex-date of July 5, 2024. Despite a recent 6-month price return of -21.46%, the company has shown strong total returns over longer periods, particularly a 1358.88% total return over the past 5 years.

Artemis Medicare Services Ltd has declared a 45% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.46%, with a dividend return of 0%, resulting in a total return of -21.46%.<BR><BR>Over the past year, the price return was 53.3%, with a dividend return of 0.25%, leading to a total return of 53.55%.<BR><BR>In the 2-year period, the price return was 205.4%, with a dividend return of 0.88%, culminating in a total return of 206.28%.<BR><BR>For the 3-year period, the price return was 472.81%, with a dividend return of 2.26%, resulting in a total return of 475.07%.<BR><BR>In the last 4 years, the price return was 860.16%, with a dividend return of 2.87%, leading to a total return of 863.03%.<BR><BR>Finally, over the past 5 years, the price return was 1353.8%, with a dividend return of 5.08%, resulting in a total return of 1358.88%.<BR><BR>Overall, Artemis Medicare has shown significant total returns over the years, particularly in the longer term, despite a recent negative price return in the last 6 months. The declared dividend indicates a commitment to returning value to shareholders, although the yield remains relatively low.